ARA-290 (Cibinetide): A Six-Module Literature Course

How this course works

This page organises the published literature on ARA-290 — the research peptide also known by the international non-proprietary name cibinetide — into six modules. Each module summarises what investigators did and what they reported, and then closes with an explicit statement of where the evidence stops. This page is for educational purposes only and is not medical advice; consult a licensed physician before acting on any health information. Nothing below is a protocol, a schedule, or a suggestion that any reader use anything. Where a dose, duration or endpoint appears, it is because a cited paper described it in that specific experiment.

Module 1 — What ARA-290 Is and How It Has Been Studied

Definition and class

ARA-290 is a short, linear peptide of eleven amino acids. Published reports describe it as an engineered, non-erythropoietic peptide derived from erythropoietin (EPO), meaning it was designed to retain a tissue-signalling property of EPO while lacking EPO's effect on red blood cell production; a 2020 in vitro study used exactly that framing in describing ARA290 as "an engineered non-erythropoietic erythropoietin-derived peptide" (PMID 32335150). A transplantation study similarly characterised it as "a nonhematopoietic erythropoietin analogue" (PMID 26683514).

Origin

The peptide was not discovered in nature as a free molecule. A 2014 pain study described ARA 290 as a peptide derived from the tertiary structure of erythropoietin — that is, modelled on a surface region of the folded EPO protein rather than on its receptor-binding face (PMID 24529189). That design logic is why the literature repeatedly separates ARA-290's signalling from erythropoiesis.

Forms and names used in research

Across publications the same molecule appears as ARA 290, ARA-290 and cibinetide; a 2017 colitis paper used the name cibinetide throughout (PMID 29026145), while human pilot trials in sarcoidosis used ARA 290 (PMID 23168581). Chemically modified research forms also exist: investigators conjugated the peptide to a DOTA chelator and labelled it with technetium-99m to create ^99mTc-DOTA-ARA-290, evaluated as a potential SPECT imaging tracer for ischemic cardiac tissue (PMID 35317117).

How it has been studied

The literature falls into three tiers: cell-culture work, rodent disease models, and a small number of short human pilot trials. An expert review of ARA 290 in sarcoidosis-associated small fibre neuropathy summarised the clinical programme as early-stage and investigational (PMID 24555851).

Limits of the evidence (Module 1): the published record establishes what ARA-290 is and where it came from, but the verified literature summarised here contains no large confirmatory trials, no head-to-head comparisons against established therapies, and no long-term human follow-up.

Module 2 — Mechanism as Described in the Literature

The receptor complex

The mechanism most consistently described is engagement of a receptor heterocomplex rather than the classical EPO receptor homodimer. Researchers reported that activation of the EPOR–β common receptor complex by cibinetide ameliorated impaired wound healing in mice with genetic diabetes, and used that receptor complex as the explanatory framework for the effect (PMID 29223734). This receptor arrangement is the reason authors describe tissue-protective signalling as separable from haematopoietic signalling (PMID 26683514).

Innate immune cells

Several papers centre on myeloid cells. In an islet transplantation model, the study reported that ARA 290 inhibited macrophage activation and prevented damage to transplanted islets (PMID 26683514). In experimental colitis, researchers reported that cibinetide dampened innate immune cell functions and that the course of disease was ameliorated (PMID 29026145). In a model of Alzheimer's-like pathology, early monocyte modulation by the peptide was reported to decelerate pathology progression (PMID 34343617).

Neural and nociceptive signalling

Two mechanistic strands relate to pain. A 2014 study reported long-term relief of neuropathic pain in a rodent model coupled with suppression of the spinal microglial response, linking the behavioural readout to glial activity (PMID 24529189). A 2016 paper proposed a more direct route, reporting that ARA 290 relieved pathophysiological pain by targeting the TRPV1 channel and framing this as integration between the immune system and nociception (PMID 26774587).

Oxidative and genotoxic stress

In vitro, researchers reported that ARA290 attenuated doxorubicin-induced genotoxicity and oxidative stress, adding a cytoprotective dimension to the mechanistic picture (PMID 32335150).

Limits of the evidence (Module 2): mechanism in these papers is inferred from model systems, not demonstrated in human tissue during treatment. Receptor-complex engagement, microglial suppression and TRPV1 involvement come from separate experimental settings and were not unified in a single study, so the relative contribution of each pathway to any reported outcome remains unresolved.

Module 3 — Reported Outcomes, Study by Study

Human pilot trials

The most cited human work is a randomised, double-blind pilot study in sarcoidosis patients with symptoms of small fibre neuropathy, in which the study administered ARA 290 at 2 mg daily by subcutaneous injection over 28 days and assessed safety alongside symptom questionnaires and functional measures (PMID 23168581). A companion 2013 report in the same population used corneal confocal microscopy as an objective structural endpoint and reported that a 28-day course of ARA 290 improved symptom scores and increased corneal nerve fibre density (PMID 24136731).

A separate randomised study in patients with type 2 diabetes examined metabolic and neuropathic endpoints over a 28-day treatment period, and researchers reported improvement in metabolic control and in neuropathic symptoms relative to control (PMID 25387363). An expert review placed these findings in context, describing ARA 290 for small fibre neuropathy in sarcoidosis as a promising but early investigational approach requiring larger trials (PMID 24555851).

Animal and cell models

Limits of the evidence (Module 3): the human trials were explicitly pilot-scale, short in duration and conducted in narrow patient groups, so their results describe what happened in those cohorts and not what would happen in a general population. The animal and cell studies used disease-specific models whose translation to humans was not established in the same papers. None of these reports constitutes evidence of benefit for any use outside the model or population tested.

Module 4 — ARA-290 Side Effects: What Studies Report

Safety reporting in this literature is limited to the small clinical studies, and it is described in general tolerability terms rather than as a detailed adverse-event catalogue.

• Sarcoidosis pilot trial. The randomised, double-blind pilot study was designed to evaluate safety as well as efficacy of ARA 290 at 2 mg daily for 28 days, and researchers reported the peptide to be well tolerated in that cohort (PMID 23168581).
• Sarcoidosis corneal nerve study. The 2013 report of 28-day dosing in sarcoidosis patients likewise described tolerability alongside its symptom and corneal nerve fibre density endpoints, without reporting a treatment-limiting safety signal (PMID 24136731).
• Type 2 diabetes trial. The 28-day randomised study in type 2 diabetes reported metabolic and neuropathic symptom outcomes without describing a safety finding that halted treatment (PMID 25387363).
• Review-level framing. An expert review of the sarcoidosis programme summarised the clinical experience as early and the tolerability data as preliminary, calling for larger studies (PMID 24555851).

A recurring theme in the mechanistic literature is that the molecule was engineered to be non-erythropoietic, which is why authors describe it as separable from EPO's haematopoietic activity (PMID 32335150, PMID 26683514). That is a design characteristic reported in these papers, not a demonstration that long-term exposure carries no haematological consequence.

Limits of the evidence (Module 4): "well tolerated" in a pilot trial of a few dozen participants over four weeks cannot detect uncommon events, delayed events, or events that emerge with prolonged exposure. The verified literature contains no long-term safety study, no dose-ranging toxicity report in humans, no pregnancy or paediatric data, and no drug-interaction study. Absence of reported adverse events in small short trials is not evidence of safety.

Module 5 — Pharmacokinetics Where Data Exist

Formal human pharmacokinetic parameters — half-life, clearance, volume of distribution, bioavailability — are not reported in the studies verified for this page. What exists is indirect.

Route and dosing frequency in trials

Human studies used subcutaneous administration on a daily schedule, as in the pilot trial that gave 2 mg daily for 28 days (PMID 23168581), and the 28-day daily-dosing design was repeated in the type 2 diabetes study (PMID 25387363). Daily dosing of a short peptide is consistent with rapid systemic elimination, but the cited papers did not publish the kinetic measurements that would confirm it.

Biodistribution from imaging work

The closest thing to distribution data comes from radiochemistry: investigators synthesised ^99mTc-DOTA-ARA-290 and evaluated it as a potential SPECT tracer for targeting the cardiac ischemic region, which required characterising where the labelled peptide accumulated (PMID 35317117). Because the tracer is a chelator-conjugated derivative rather than the unmodified peptide, its behaviour is not automatically interchangeable with that of ARA-290 itself.

Durability of effect versus drug exposure

One rodent study reported long-term relief of neuropathic pain that outlasted the dosing period, which the authors linked to suppression of the spinal microglial response rather than to sustained peptide presence (PMID 24529189). Effect duration and drug exposure are therefore reported as distinct concepts in this literature.

Limits of the evidence (Module 5): no verified paper here reports human plasma concentrations, half-life, metabolism, renal or hepatic handling, or the effect of organ impairment. Dosing schedules used in trials describe those trials only and cannot be generalised.

Module 6 — Regulatory Status, Stated Factually

The following is a factual description of status, not legal advice.

• No approved product. Cibinetide/ARA-290 is not the active ingredient of any medicine approved by the US Food and Drug Administration or the European Medicines Agency. Its human use in the literature occurred inside investigational clinical studies, such as the randomised double-blind pilot trial in sarcoidosis (PMID 23168581) and the randomised study in type 2 diabetes (PMID 25387363).
• Investigational framing in the literature. A 2014 expert review discussed ARA 290 explicitly as an investigational drug for small fibre neuropathy in sarcoidosis, which is how the compound is categorised in peer-reviewed sources (PMID 24555851).
• Research-use-only material. Peptide material supplied for laboratory work is labelled research use only (RUO). RUO material is not manufactured, tested or released as a drug product, and RUO labelling is not a statement of human safety or quality.
• Compounding. In the United States, a substance may be compounded by a pharmacy only if it meets the statutory conditions in sections 503A/503B of the Federal Food, Drug, and Cosmetic Act — broadly, being a component of an approved drug, appearing in an applicable USP monograph, or being listed by FDA as eligible for compounding. Peptides that satisfy none of these categories are not lawfully compoundable, and status can change as agency lists are revised.
• Distinct from approved erythropoietins. Approved erythropoiesis-stimulating agents are separate, larger biologic products; ARA-290 is described in the literature as a non-erythropoietic peptide engineered from erythropoietin and is not an erythropoietin product (PMID 32335150, PMID 26683514).

Limits of the evidence (Module 6): regulatory categories describe legal and manufacturing status only. They say nothing about whether a compound works, and a peptide's appearance in published research does not indicate approval, availability or acceptable use.

What the Studies Did Not Test

Reading the verified literature as a whole, several gaps are explicit:

1. Healthy people. Human data came from patients with sarcoidosis-associated small fibre neuropathy (PMID 24136731) and type 2 diabetes (PMID 25387363); performance, recovery or general wellness endpoints in healthy volunteers were not studied.
2. Long exposure. The human studies ran for weeks, not months or years, as in the 28-day pilot design (PMID 23168581).
3. Hard clinical outcomes. Rodent and cell studies measured surrogate markers — microglial activation, monocyte phenotype, wound closure, oxidative stress markers — rather than survival or disease-modification in humans (PMID 24529189, PMID 34343617, PMID 29223734, PMID 32335150).
4. Combinations. No verified study examined ARA-290 together with other peptides or with common medications.
5. Human mechanism confirmation. TRPV1 involvement was reported in experimental pain models (PMID 26774587) and immune modulation in colitis models (PMID 29026145), but neither was confirmed in treated human tissue.
6. Non-clinical formulations. Imaging work used a chelator-conjugated derivative, not the peptide as dosed in trials (PMID 35317117).

The honest summary is that ARA-290 has a coherent mechanistic story, a handful of small positive pilot trials, and a large unfilled space where confirmatory human evidence would go. This page is educational only and is not medical advice; questions about any medical condition belong with a licensed physician.

References

• Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study (Molecular Medicine, 2012)
• ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density (Molecular Medicine, 2013)
• ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response (Molecular Pain, 2014)
• ARA 290 for treatment of small fiber neuropathy in sarcoidosis (Expert Opinion on Investigational Drugs, 2014)
• ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes (Molecular Medicine, 2015)
• A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets (Transplantation, 2016)
• ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception (Peptides, 2016)
• Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis (Scientific Reports, 2017)
• Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes (BBA Molecular Basis of Disease, 2018)
• An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress (Toxicology in Vitro, 2020)
• Synthesis and evaluation of 99mTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region (Iranian Journal of Basic Medical Sciences, 2021)
• Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression (Brain, Behavior, and Immunity, 2022)